Construction of Training Datasets for an AI-Assisted Precision Diagnosis and Treatment System for Cholangiocarcinoma and a Prospective, Multicenter, Randomized Controlled Clinical Trial Based on This System

INTERVENTION: Non‐AI Assisted Diagnosis and Treatment Group:Non‐AI Assisted Diagnosis or Treatment;AI Assisted Diagnosis and Treatment Group:AI Assisted Diagnosis and Treatment;Observation group:None; CONDITION: Cholangiocarcinoma PRIMARY OUTCOME: R0 resection rate in surgical patients;Tumor progression‐free rate and disease response rate in non‐surgical patients;Diagnostic accuracy of preoperative lymph node metastasis; SECONDARY OUTCOME: 3‐year disease‐free survival rate;30‐day major complication rate after surgery;Surgical operation and postoperative recovery indicators;3‐year overall survival rate;Tumor marker decline rate in non‐surgical patients; INCLUSION CRITERIA: 1.Patients aged 18 to 80 years old; 2.Preoperative imaging and laboratory examinations suggest cholangiocarcinoma, confirmed by postoperative pathology (surgical patients) or puncture pathology (non‐surgical patients); 3.Patients have autonomous capacity, understand and voluntarily sign written informed consent, and can complete the follow‐up plan; 4.Signed written informed consent before trial screening;